RadNet, Inc.

RadNet, Inc.

RDNTNYSE / NASDAQHealthcareMid cap

$69.71+$0.20 (+0.3%)

Last close · Data as of Nov 20, 2026

Market cap
$4.2B
P/E
-222.6x
EV / EBITDA
16.7x
Revenue
$2.0B
Net margin
-0.9%
ROCE
2.6%

-12.0% over the last year

RadNet, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+0.1%
3M
-9.5%
6M
+28.6%
1Y
-12.0%
5Y
+146.3%

52-week range

Day change +$0.20 (+0.3%) from $70 to $70 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in RDNT, bought on each weekday since 2021.

News & filings

What RadNet filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 18.7 million US dollars in fiscal 2025.

Strengths (1)

  • Revenue grew 11.5% in fiscal 2025.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health.

Read moreShow less

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

Sector
Healthcare
Shares outstanding
77.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$4.2B
P/E
-222.6x
P/B
3.8x
EV / EBITDA
16.7x
EV / Sales
2.6x
P/S
2.0x
52-week high
$84.48
52-week low
$51.87

Profitability

Operating margin
4.1%
Net margin
-0.9%
EBITDA margin
15.4%
ROE
-1.7%
ROCE
2.6%
ROA
-0.5%
Asset turnover
0.54

Growth

Revenue
$2.0B
Revenue growth, 1Y
11.5%
Revenue CAGR, 3Y
12.6%
Net profit growth, 1Y
-767.8%
Free cash flow
$85.6M

Solvency

Current ratio
1.76
Debt / Equity
1.71
Debt / Assets
0.49
CFO / Net profit
-16.02
Cash / Market cap
18.5%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$2.0B
Cost of revenue$1.8B
Gross profit$235.5M
Operating expenses$152.1M
Operating income$83.4M
Interest and other-$51.5M
Pretax income$31.9M
Tax and other$50.6M
Net income-$18.6M

Revenue and net profit

Revenue grew 11.5% in FY2025; net profit is the dashed line.

RadNet, Inc. revenue and net profit by fiscal year
RadNet, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.4B$10.7M
FY2023$1.6B$3.0M
FY2024$1.8B$2.8M
FY2025$2.0B-$18.7M

Cash flows

FY2025: $298.8M from operations, $85.6M free after investment (dashed).

RadNet, Inc. operating and free cash flow by fiscal year
RadNet, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$146.4M$27.0M
FY2023$220.9M$44.3M
FY2024$233.0M$45.0M
FY2025$298.8M$85.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.0B+11.5%1Y
EBITDA
$313.8M-2.9%1Y
Net profit
-$18.7M-767.8%1Y
Cash from operations
$298.8M+28.2%1Y
Free cash flow
$85.6M+90.4%1Y
Revenue CAGR, 3Y
12.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.0B$313.8M-$18.7M$85.6M-1.7%+11.5%-767.8%

Monthly returns

Month-by-month returns of RDNT across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.8B
Liabilities$2.4B
Equity$1.4B
Paid-in capital$1.2B
Retained earnings-$95.4M
Minority interest$266.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; RDNT highlighted.

P/E against peers

RDNT has no positive P/E; the peer median is 31.9x.

Not shown (no positive earnings and no EV / Sales): RadNet, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
RadNet, Inc.RDNTthis company$4.2B-222.6x3.8x-1.7%16.7x
Ligand Pharmaceuticals IncorporatedLGND$4.7B38.0x4.6x12.2%25.3x
Indivior Pharmaceuticals, Inc.INDV$4.4B21.1x-44.7x-212.1%15.1x
Amneal Pharmaceuticals, Inc.AMRX$4.3B59.9x-60.9x-101.8%11.1x
Veracyte, Inc.VCYT$4.0B60.1x3.0x5.1%40.9x
Waystar Holding Corp.WAY$3.9B34.6x1.0x2.9%13.6x
Catalyst Pharmaceuticals, Inc.CPRX$3.8B17.9x4.0x22.5%10.6x
Merit Medical Systems, Inc.MMSI$3.8B29.3x2.4x8.1%12.5x
ACADIA Pharmaceuticals Inc.ACAD$3.7B9.5x3.0x31.9%30.8x
Peer median—31.9x2.7x6.6%14.3x

Year-to-date ROI

RDNT since 1 January, against earlier years.

Historical volatility

RDNT's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

RadNet, Inc. operating margin by fiscal year
RadNet, Inc. operating margin by fiscal year
DateOperating margin
FY20223.5%
FY20235.8%
FY20246.1%
FY20254.1%
LineFY2025
Cost of revenueCost Of Revenue$1.8B
Gross profitGross Profit$235.5M
Operating expensesOperating Expense$152.1M
Other operating expensesOther Operating Expenses—
Depreciation and amortisationDepreciation And Amortization In Income Statement$152.1M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$152.1M
Rent expense supplementalRent Expense Supplemental—
Total expensesTotal Expenses$2.0B
Pretax incomePretax Income$31.9M

Learn while you research

Academy chapters picked for RadNet, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 1.71 is elevated, understand what that means for solvency.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →